Efficacy and Safety of Dupilumab in Clinical Practice: One Year of Experience on 165 Adult Patients from a Tertiary Referral Centre.
Atopic dermatitis
Daily practice
Dupilumab
Eczema
Severity
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
12
2020
pubmed:
14
3
2021
medline:
14
3
2021
entrez:
13
3
2021
Statut:
ppublish
Résumé
We have read with great interest the article by Kreeshan et al., which reported data on effectiveness and laboratory safety of dupilumab. We performed a retrospective study including 165 adult patients affected by moderate-to-severe atopic dermatitis (AD) and treated with dupilumab for at least 52 weeks. A significant improvement in eczema area severity index (EASI) score after 16 and 52 weeks of treatment with dupilumab was observed. The mean EASI score at baseline was 28.84 ± 6.4 and significantly reduced to 10.05 ± 8.00 at 16 weeks (p < 0.001), and to 3.04 ± 4.73 at 52 weeks (p < 0.001), with a mean percentage reduction of 65.15% and 89.45%, respectively. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores (P-NRS, S-NRS and DLQI). Furthermore, no patient discontinued the drug because of inefficacy. Fifty-seven out of 165 (34.54%) patients reported at least one adverse event (AE) during the 52-week treatment. Our study confirms that dupilumab can represent a long-term treatment for moderate-to-severe adult AD, beyond 16 weeks. In our experience, dupilumab demonstrated a favourable safety profile at 52 weeks and only a few patients had to discontinue the treatment because of AEs.
Identifiants
pubmed: 33712985
doi: 10.1007/s13555-021-00505-z
pii: 10.1007/s13555-021-00505-z
pmc: PMC8018995
doi:
Types de publication
Letter
Langues
eng
Pagination
355-361Références
Kreeshan FC, Al-Janabi A, Warren RB, Hunter HJA. Real-world experience and laboratory monitoring of dupilumab in patients with moderate to severe atopic dermatitis in a tertiary centre. Dermatol Ther (Heidelb). 2020. https://doi.org/10.1007/s13555-020-00469-6
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in AD. N Engl J Med. 2016;375:2335–48.
doi: 10.1056/NEJMoa1610020
De Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroids in adult patients with AD who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083–101.
doi: 10.1111/bjd.16156
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe AD with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2017;389:2287–303.
doi: 10.1016/S0140-6736(17)31191-1
Nettis E, Fabbrocini G, Ortoncelli M, et al. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19577 .
doi: 10.1111/bjd.19577
pubmed: 32998177
Ariëns LF, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.08.127 .
doi: 10.1016/j.jaad.2020.08.127
pubmed: 32946967
Fargnoli MC, Esposito M, Ferrucci S, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatol Treat. 2020. https://doi.org/10.1080/09546634.2020.1773379 .
doi: 10.1080/09546634.2020.1773379
Hello M, Aubert H, Bernier C, Néel A, Barbarot S. Dermatite atopique de l'adulte [Atopic dermatitis of the adult]. Rev Med Interne. 2016;37(2):91–9. https://doi.org/10.1016/j.revmed.2015.10.345 [Article in French].
Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82:1530–2.
doi: 10.1016/j.jaad.2020.02.029
Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181(5):1072–4.
doi: 10.1111/bjd.18041
Faiz S, Giovannelli J, Podevin C, et al. Groupe de Recherche sur l'Eczéma aTopique (GREAT), France. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143–51.
Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82(6):1530–2. https://doi.org/10.1016/j.jaad.2020.02.029 .
doi: 10.1016/j.jaad.2020.02.029
pubmed: 32074486